Abstract
Extrapolation of this evidence of carcinogenesis from rodents to humans is an uncertain process. Longer-term clinical trials and careful postmarketing surveillance during the next several decades are needed to determine whether cholesterol-lowering drugs cause cancer in humans. In the meantime, the results of experiments in animals and humans suggest that lipid-lowering drug treatment, especially with the fibrates and statins, should be avoided except in patients at high short-term risk of coronary heart disease.
Keywords
MedicineClinical trialCarcinogenDrugPharmacologyCancerBioinformaticsInternal medicine
Affiliated Institutions
Related Publications
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
This study investigated the metabolic interaction between fibrates and statin hydroxy acids in human hepatocytes. Gemfibrozil (GFZ) modestly affected the formation of beta-oxida...
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
BACKGROUND HMG CoA reductase inhibitors (or statins), a new class of lipid-lowering compounds, have raised expectations for more widespread use than that of the older lipid-lowe...
Animal studies addressing the carcinogenicity of TCDD (or related compounds) with an emphasis on tumour promotion
Dioxin and certain structurally related compounds increase the incidence of liver neoplasms in rodents upon chronic bioassay. Short-term studies indicate the lack of direct DNA-...
Statins: Beneficial or Adverse for Glucose Metabolism
Large-scale clinical trials have established that statin use for lowering blood cholesterol is beneficial in reducing atherosclerotic cardiovascular diseases in different popula...
Should there be a moratorium on the use of cholesterol lowering drugs?
2][3][4] The degree of disagreement is surprising as they review essentially the same data, from clinical trials of cholesterol lowering by drugs or by diet.There is agreement a...
Publication Info
- Year
- 1996
- Type
- letter
- Volume
- 275
- Issue
- 1
- Pages
- 55-55
- Citations
- 372
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
372
OpenAlex
Cite This
Thomas B. Newman
(1996).
Carcinogenicity of Lipid-Lowering Drugs.
JAMA
, 275
(1)
, 55-55.
https://doi.org/10.1001/jama.1996.03530250059028
Identifiers
- DOI
- 10.1001/jama.1996.03530250059028